Shire’s new office will serve as the base for preparations for the future commercialization of its pipeline products in Japan.
In his new role, Mr Fujiwara will oversee the implementation and development of clinical and regulatory strategies for the commercialization of products in the human genetic therapies pipeline, as well as identify potential future opportunities for growth in this market. Mr Fujiwara will also work closely with Japanese physicians and regulatory authorities to ensure the needs of affected patients and their families are being met.
In addition to the Japan representative office, Shire has offices in Singapore and Australia, and plans to continue exploring additional opportunities for growth throughout the Asia Pacific region.
Sylvie Gregoire, president of human genetic therapies at Shire, said: Through the opening of this new office, we have taken a significant step toward increasing our presence in this market. Soh Fujiwara joins Shire at a critical time in our global expansion, and we look forward to working closely with him and his team to build an infrastructure that will enable us to bring additional therapies to Japanese patients.